"In the multicentre retrospective study we analyzed 96 consecutive AML patients >= 50 years allografted with related (n=59) or unrelated (n=37) donor. The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896). The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011). Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.009) were also the only independent variables associated with inferior DFS. In conclusion, our analysis indicates that outcomes of allografted AML patients aged >= 50 years are determined by cytogenetic risk category and disease status at transplantation and not by the type of donor." . "Mu\u017E\u00EDk, J." . "Neoplasma" . "Raida, L." . "Indr\u00E1k, K." . . "AML; allogeneic HSCT; age; donor"@en . "8"^^ . . "RIV/00023736:_____/13:00010718!RIV14-MZ0-00023736" . . "The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients less or equal than 50 years from the Czech acute leukaemia clinical register (alert)" . "1"^^ . "Jindra, P." . "Koz\u00E1k, T." . . "SK - Slovensk\u00E1 republika" . "RIV/00023736:_____/13:00010718" . . . . "The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients less or equal than 50 years from the Czech acute leukaemia clinical register (alert)" . . "5" . . "Koza, V." . "11"^^ . . "Karas, M." . . "Cetkovsk\u00FD, Petr" . "O" . "Szotkowski, T." . "\u017D\u00E1k, P." . "60" . "10.4149/neo_2013_075" . "The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients less or equal than 50 years from the Czech acute leukaemia clinical register (alert)"@en . "0028-2685" . . "In the multicentre retrospective study we analyzed 96 consecutive AML patients >= 50 years allografted with related (n=59) or unrelated (n=37) donor. The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896). The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011). Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.009) were also the only independent variables associated with inferior DFS. In conclusion, our analysis indicates that outcomes of allografted AML patients aged >= 50 years are determined by cytogenetic risk category and disease status at transplantation and not by the type of donor."@en . "[66B44D57AC87]" . . . "Al Sabty, F." . . . "94888" . "The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients less or equal than 50 years from the Czech acute leukaemia clinical register (alert)"@en .